Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
1. Participation on 1 September 2008 (transitional provision of the law of May 2, 2007 on the disclosure of large shareholdings). Wellington Management Company, LLP having its registered offices at 75 State Street, Boston, MA 02109, United States of America, notified having voting discretion over a number of shares crossing the threshold of 3% of UCB's capital (6,350,530 shares on a total of 183,365,052 or 3.46%).
2. According to article 14 § 6 of the royal decree of 14 February 2008 on the disclosure of large shareholdings. Wellington Management Company, LLP having its registered offices at 75 State Street, Boston, MA 02109, United States of America, notified having sold a number of UCB shares with voting rights on October 28, 2008 making it cross the lowest statutory threshold for notification (being 3%).
About UCB UCB, Brussels, Belgium (www.ucb-group.com) is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative medicines focused on central nervous system and immunology disorders. Employing more than 10,000 people in over 40 countries, UCB achieved revenues of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).
For the pdf-version of this press release, please click on the link below:
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
